title: Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma.
abstract: The progression from in situ to invasive breast carcinoma is still an event poorly understood. However, it has been suggested that interactions between the neoplastic cells and the tumor microenvironment may play an important role in this process. Thus, the determination of differential tumor-stromal metabolic interactions could be an important step in invasiveness. The expression of stromal Caveolin-1 (Cav-1) has already been implicated in the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). Additionally, stromal Cav-1 expression has been associated with the expression of stromal monocarboxylate transporter 4 (MCT4) in invasive breast cancer. However, the role of stromal MCT4 in invasiveness has never been explored, neither the association between Cav-1 and MCT4 in the transition from breast DCIS to IDC. Therefore, our aim was to investigate in a series of breast cancer samples including matched in situ and invasive components, if there was a relationship between stromal Cav-1 and MCT4 in the progression from in situ to invasive carcinoma. We found loss of stromal Cav-1 in the progression to IDC in 75% of the cases. In contrast, MCT4 stromal expression was acquired in 87% of the IDCs. Interestingly, a concomitant loss of Cav-1 and gain of MCT4 was observed in the stroma of 75% of the cases, when matched in situ and invasive carcinomas were compared. These results suggest that alterations in Cav-1 and MCT4 may thus mark a critical point in the progression from in situ to invasive breast cancer.
authors.affiliation: Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
authors.forename: Diana
authors.initials: D
authors.lastname: Martins
authors.forename: Francisco F
authors.initials: FF
authors.lastname: Beça
authors.forename: Bárbara
authors.initials: B
authors.lastname: Sousa
authors.forename: Fátima
authors.initials: F
authors.lastname: Baltazar
authors.forename: Joana
authors.initials: J
authors.lastname: Paredes
authors.forename: Fernando
authors.initials: F
authors.lastname: Schmitt
mesh_terms: D001943:Breast Neoplasms / Q000503:physiopathology*; D051242:Caveolin 1 / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D027501:Monocarboxylic Acid Transporters / Q000378:metabolism*; D009124:Muscle Proteins / Q000378:metabolism*; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D059016:Tumor Microenvironment / Q000502:physiology*
chemical_list: C495540:CAV1 protein, human; D051242:Caveolin 1; D027501:Monocarboxylic Acid Transporters; D009124:Muscle Proteins; C406962:SLC16A4 protein, human
keywords: Caveolin-1; DCIS; IDC; MCT4; breast cancer; immunohistochemistry; stroma; tumor progression; tumour progression
references.citation: Breast Cancer Res Treat. 2012 Jan;131(1):1-15
references.pmid: 21901387
references.citation: Oncogene. 2006 Apr 13;25(16):2328-38
references.pmid: 16314837
references.citation: Cancer Res. 2009 Apr 1;69(7):2878-86
references.pmid: 19318577
references.citation: J Cancer. 2012;3:175-83
references.pmid: 22514560
references.citation: Breast Cancer Res. 2008;10(5):R87
references.pmid: 18928525
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9
references.pmid: 12714683
references.citation: Sci Transl Med. 2011 Nov 9;3(108):108ra113
references.pmid: 22072638
references.citation: Breast Cancer Res. 2006;8(5):R61
references.pmid: 17069663
references.citation: N Engl J Med. 2009 Feb 19;360(8):790-800
references.pmid: 19228622
references.citation: Cell Cycle. 2011 Jun 1;10(11):1772-83
references.pmid: 21558814
references.citation: Cell. 2011 Jul 8;146(1):148-63
references.pmid: 21729786
references.citation: Cancer Biol Ther. 2010 Jul 15;10(2):135-43
references.pmid: 20431349
references.citation: Am J Pathol. 2009 Jun;174(6):2035-43
references.pmid: 19411449
references.citation: Breast Cancer Res Treat. 2012 Jun;133(3):1009-24
references.pmid: 22134623
references.citation: Neuro Oncol. 2013 Feb;15(2):172-88
references.pmid: 23258846
references.citation: Breast Cancer Res Treat. 2012 Aug;135(1):153-65
references.pmid: 22718308
references.citation: Clin Cancer Res. 2007 Jan 1;13(1):90-101
references.pmid: 17200343
references.citation: Am J Pathol. 2009 Jun;174(6):2023-34
references.pmid: 19411448
references.citation: Int J Gynecol Pathol. 2008 Oct;27(4):568-74
references.pmid: 18753962
references.citation: Cancer Res. 2006 May 15;66(10):5278-86
references.pmid: 16707453
references.citation: Cell Cycle. 2011 Jun 1;10(11):1794-809
references.pmid: 21521946
references.citation: Biochem J. 2000 Aug 15;350 Pt 1:219-27
references.pmid: 10926847
references.citation: Cell Cycle. 2010 May 15;9(10):1960-71
references.pmid: 20495363
references.citation: J Bioenerg Biomembr. 2012 Feb;44(1):127-39
references.pmid: 22407107
references.citation: Aging (Albany NY). 2010 Apr;2(4):185-99
references.pmid: 20442453
references.citation: Hum Pathol. 2011 Oct;42(10):1438-46
references.pmid: 21450330
references.citation: Cancer Biol Ther. 2009 Jun;8(11):1071-9
references.pmid: 19502809
references.citation: Cancer Cell. 2008 May;13(5):394-406
references.pmid: 18455123
references.citation: Cell Cycle. 2012 Mar 15;11(6):1108-17
references.pmid: 22313602
references.citation: Int J Surg Pathol. 2010 Jun;18(3 Suppl):170S-173S
references.pmid: 20484285
references.citation: Breast Cancer Res. 2009;11(1):R7
references.pmid: 19187537
references.citation: Annu Rev Pathol. 2012;7:423-67
references.pmid: 22077552